Meeting
2013 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
Authors
Sarah Leary
Seattle Children's, Seattle, WA
Sarah Leary , Julie R. Park , Joel M. Reid , Andrew T. Ralya , Sylvain Baruchel , Bing Wu , Ashish M Ingle , Charlotte H Ahern , Brenda Weigel , Susan Blaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Angiogenesis
Clinical Trial Registration Number
NCT01538095
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2538)
DOI
10.1200/jco.2013.31.15_suppl.2538
Abstract #
2538
Poster Bd #
1F
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
First Author: Eric Schafer
Poster
2014 ASCO Annual Meeting
A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study.
First Author: James I. Geller
Poster
2012 ASCO Annual Meeting
Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.
First Author: Rochelle Bagatell
Poster
2011 ASCO Annual Meeting
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.
First Author: T. R. Hummel